TransMedics Group, Inc. (TMDX) Debt to Assets Ratio: 0.44%
The debt to assets ratio for TransMedics Group, Inc. (TMDX) is 0.44% as of Saturday, June 20, 2026.
TMDX Debt to Assets Ratio Metrics
DEBT TO ASSETS RATIO
0.44%
TMDX Competitors' Debt to Assets Ratio
| NAME | MARKET CAP | DEBT TO ASSETS RATIO |
|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.72B | 0.44% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | 0.45% |
| 23andMe Holding Co. (ME)vs › | $15.31M | 0.43% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 0.14% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | 0.52% |
| Tempus AI, Inc. (TEM)vs › | $8.87B | 0.58% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | 0.43% |
| Baxter International Inc. (BAX)vs › | $10.27B | 0.50% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.42% |
| Revvity, Inc. (RVTY)vs › | $11.16B | 0.29% |
Leverage Ratios Comparison
Debt/Assets
0.4%
Debt/Equity
0.99
Current Ratio
7.14
Interest Coverage
7.9x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
- Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
- Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
- Both measure leverage but from different perspectives
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
TransMedics Group, Inc. Debt to Assets Ratio Formula & Definition
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. Debt to Assets Ratio FAQ
- What is the debt to assets ratio for TransMedics Group, Inc. (TMDX)?
- The debt to assets ratio for TMDX stock is 0.44%.
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein